Alzheimer's disease

Bristol Myers’ stock decline in response to weak guidance is a gift to investors
Health

Bristol Myers’ stock decline in response to weak guidance is a gift to investors

Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per […]

Read More
Novo Nordisk’s diabetes drug Ozempic may reduce the risk of Alzheimer’s disease, study says
Health

Novo Nordisk’s diabetes drug Ozempic may reduce the risk of Alzheimer’s disease, study says

Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk‘s blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer’s disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday.  Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk […]

Read More
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
Health

Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment

Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease.  But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi, […]

Read More
GEHC gives reasons to look beyond temporary China woes and shares reverse higher
Health

GEHC gives reasons to look beyond temporary China woes and shares reverse higher

GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue advanced less than 1% year over […]

Read More
CNBC Daily Open up: Tesla soars, S&P closes over 5,500
World

CNBC Daily Open up: Tesla soars, S&P closes over 5,500

This report is from today’s CNBC Daily Open, our intercontinental marketplaces e-newsletter. CNBC Everyday Open delivers traders up to pace on every little thing they need to know, no matter wherever they are. Like what you see? You can subscribe here. Traders function on the flooring of the New York Inventory Trade during morning investing on […]

Read More
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year
Health

Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer’s treatment, donanemab, and expects the agency to make a decision by the end of the year. Eli Lilly is […]

Read More
Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know
Health

Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know

The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Medicare has agreed to pay for the Alzheimer’s treatment Leqembi, a major turning point for patients who are diagnosed with the early stages of the disease. Leqembi is the only drug on the […]

Read More
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Health

Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024

Jay Reinstein, who suffers from Alzheimer’s, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty Images Sales of the Alzheimer’s drug Leqembi may be slow initially due to logistical requirements but could pick […]

Read More
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Business

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

The Food and Drug Administration on Thursday approved the Alzheimer’s treatment Leqembi, a pivotal decision that is expected to expand access to the expensive drug for older Americans. Medicare has promised to start covering Leqembi, with some conditions, on the same day the FDA approves the antibody treatment. Leqembi is made by Japanese pharmaceutical company […]

Read More
FDA advisors weigh whether Alzheimer’s drug Leqembi should receive full approval
Health

FDA advisors weigh whether Alzheimer’s drug Leqembi should receive full approval

[The stream is scheduled to begin at 10 a.m. ET. Please refresh the page if you don’t see a player above at that time.] A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer’s drug Leqembi, made by Eisai and Biogen, should receive […]

Read More